Lamisil (Terbinafine Hydrochloride)

Terbinafine Hydrochloride blocks the fungal enzyme squalene epoxidase, which is essential for producing ergosterol, a key component of fungal cell membranes. Inhibiting this step leads to toxic buildup of squalene and loss of membrane integrity, ultimately killing the fungal cells and stopping the infection.

The specific dosage and frequency of Lamisil are determined by the prescribing healthcare professional based on the infection type, severity, patient age, and treatment area. Patients should follow the prescriber’s instructions and the product label for proper application.

Safety data for topical terbinafine during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Lamisil.

To place an order, submit an enquiry on the Lamisil product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lamisil belongs to the allylamine class, which differs from azole antifungals that inhibit a later step in ergosterol synthesis. Allylamines like terbinafine often achieve faster fungal clearance and may be preferred for certain dermatophyte infections, though choice depends on infection type, patient factors, and physician judgment.

Lamisil should be stored at room temperature, typically below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Lamisil is applied topically to the affected skin area. Clean and dry the area before use, then spread a thin layer of the cream or gel as directed by the prescriber, usually once or twice daily. Wash hands after application unless the hands are the treatment site.

While rare, serious adverse reactions can include severe allergic responses such as anaphylaxis, extensive skin rashes like Stevens‑Johnson syndrome, and liver toxicity indicated by abnormal liver function tests. Patients should seek immediate medical attention if they notice signs of a serious reaction.

Lamisil should not be used on broken or inflamed skin, on mucous membranes, or by individuals with a known hypersensitivity to terbinafine or any component of the formulation. Patients with severe liver disease should also avoid use unless specifically advised by a physician.